tbuckley/cabot-search huggingface dataset:
Abstract 1470: The association of miR-21, HER-2/neu, and PTEN expression and clinical outcome of breast cancer
Authors: Hsiao-Ching Lin, Ya-Wen Cheng, Nan-Yung Hsu
Journal: Cancer Research (2014)

Abstract Objective: Over the last decade, the incidence of breast cancer increased year by year, and the mortality rate is the top of female cancer in Taiwan. Previous study showed that overexpression of miR-21 was associated with recurrence in breast cancer. The aim of this study was to analyze the association of miR-21 expression and clinic pathologic data and to investigate whether the effect of miR-21 through PTEN pathway. Materials and Methods: A total of 120 female breast cancer patients, who were enrolled at a single medical center in Taichung. MiR-21, PTEN, hormone receptor (estrogen receptor,progesterone receptor) and HER-2 (human Epidermal Growth Factor Receptor 2) receptor were analyzed by quantitative RT-PCR. The function of invasion and migration of four breast cancer cell lines (T-47D, MDA-MB-231, MCF-7 and BT-474) were analyzed by invasion and migration assay and wound healing assay. Results: Our data showed that no significantly difference was found between miR-21 and PTEN. MiR-21 expression was positive correlated with HER-2/neu mRNA levels (P=0.038). Patients with high miR-21 level had poor disease-free survival (p=0.047) compared with low miR-21 level patients. In addition, patients with high PTEN level had poor disease-free survival (P=0.024). We also found that patients with miR-21 high/ HER-2/neu high or miR-21 high/ PTEN high had poor disease-free survival (miR-21/HER-2/neu, p=0.009; miR-21/PTEN, p=0.003). Thus, we suggested that the expressions of miR-21, HER-2/neu and PTEN play important roles in prognosis and associated with recurrence in breast cancer. These results were also confirmed in cell model experiments. Conclusion: In this study, we found that the expression of miR-21, HER-2/neu, and PTEN were associated with the recurrence of breast cancer in Taiwan. Thus, we suggested that the other pathways maybe involved in miR-21 mediated pathogenesis of breast cancer. Citation Format: Hsiao-Ching Lin, Ya-Wen Cheng, Nan-Yung Hsu. The association of miR-21, HER-2/neu, and PTEN expression and clinical outcome of breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1470. doi:10.1158/1538-7445.AM2014-1470
Abstract 12421: Single Beat Simultaneous Left Atrioventricular Strain-Volume Analysis Using Speckle Tracking Echocardiography
Authors: Alaa M Omar, Mohamed A Abdel-Rahman, Zaid H Sabe-Eleish, Osama Rifaie, Gianni Pedrizzetti, Partho P Sengupta
Journal: Circulation (2014)

Introduction: Assessment of cardiac mechanics in relation to left atrial (LA) and ventricular (LV) structural (shape and volume) changes represent a foundation for assessing cardiac remodeling in heart failure (HF) patients. We tested the feasibility of assessing simultaneous LA and LV volumes and deformation within an index cardiac cycle as a marker of total left heart structural and functional remodeling in HF. Methods: Echocardiography was performed in total 101 patients, which included 77 patients with HF (50 had normal EF (HFNEF) and 27 had reduced EF (HFREF)) and 24 young subjects with no structural heart disease (controls) (table 1). Two-dimensional speckle tracking was performed in apical 2- and 4- chamber views for simultaneous measurement of LV and LA volumes and deformation. Peak longitudinal average atrio-ventricular strain (AVS) and early diastolic strain rate (AVSR-E), in addition to the total left heart volume (TLV) during LV systole and diastole (TLVsystole, TLVdiastole), were measured. Occurrence of major adverse cardiac events (MACE) was defined during follow up. Results: In comparison with younger controls, patient with HF showed higher TLV and nearly 50% reduction in AVS and AVSR-E (table 1). These differences persisted even after adjusting for age. During a median follow up of 7 months, MACE occurred in 15 patients (5 hospitalization for heart failure, 1 cerebrovascular stroke, and 9 cardiac deaths). AVS and AVSR-E were predictors for MACE after adjusting for age (HR=0.9, 95% CI: 0.81 to 0.99, p=0.038; HR= 0.14, 95% CI: 0.02 to 0.89, p=0.037; respectively). AVS and AVSR-E had similar diagnostic values in predicting MACE (AUC= 0.77 and 0.79; p=0.001 and &lt;0.001 respectively), with higher event free survival seen for AV-S&gt;14.5%, and AVSR-E&gt;0.92 s-1 (Figure 1). Conclusion: Single beat combined assessments of LA-LV strain and strain rates may be useful integrated markers of total left heart function.
&lt;italic&gt;α&lt;/italic&gt;-Keto Acids in Tissue Culture. II. Studies on the Used Medium
Authors: Westfall Bb, Peppers Ev, Earle Wr
Journal: JNCI Journal of the National Cancer Institute (1960)

Eleven mammalian cell strains, 9 from the tissues of the C3H/HeN mouse and 2 of human origin, were examined for the quantity of keto acids that during growth they contributed to the used medium, in excess of that supplied by the medium. At 72 hours after fluid renewal, the cells had added the indicated quantities of keto acids as µmoles per 100 million cells per 100 ml. of medium: strain 721 of mouse liver epithelial origin, 730; strain 1469 of single cell origin from strain 721, 800; strain 1795 hepatoma rising from strain 1469, 640; sarcoma strain 929L, 430; strain 2071, a strain from 929L adapted to growth in protein-free medium, 500; high sarcoma fibroblast strain 1742, 225; low sarcoma strain 2049, 226; high sarcoma strain 1745, 620; high sarcoma strain 2050, 285; human epidermal strain 2198, 425; and human cervical carcinoma strain 1985 (HeLa), 232. The horse serum of the mediums used for all strains except 2071 contained the transaminase activities for the glutamic-oxalacetic and glutamic-pyruvic transaminations. However, incubation of the medium in the absence of cells produced little change in the keto acid content of the medium. The cells of strain 1469 were broken up and their extracts were found to have active transaminating enzyme systems. It would appear that the excess keto acids put into the mediums by growth of the cells reflect the metabolic activity of the cells.
Abstract 11: Is the Outcome from Witnessed VF Cardiac Arrest Improved by Providing More CPR? Results from DEFI2005, a Randomized Controlled Trial of two AED Protocols
Authors: Daniel Jost, Isabelle L Banville, Olivier Hersan, Frederique Briche, David Fontaine, David Lallement, Franck Calamai, Fred W Chapman, Jean-Luc Petit, Claude Fuilla
Journal: Circulation (2008)

Several before/after studies have found that the Guidelines 2005 CPR protocol improved cardiac arrest outcomes compared with historical cohorts treated with Guidelines 2000. These results support t...
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension
Authors: K. Reich, J.-P. Ortonne, A.B. Gottlieb, I.J. Terpstra, G. Coteur, C. Tasset, P. Mease
Journal: British Journal of Dermatology (2012)

Certolizumab pegol (CZP) is a PEGylated antitumour necrosis factor agent.To evaluate the efficacy and safety of CZP in patients with plaque psoriasis.In a randomized, placebo-controlled, double-blind study, 176 patients with moderate to severe psoriasis received placebo or CZP 400 mg at week 0 followed by placebo or CZP (200 or 400 mg) every other week until week 10. Co-primary endpoints were ≥ 75% improvement from baseline in Psoriasis Area and Severity Index (PASI 75) and a Physician's Global Assessment (PGA) of clear-almost clear at week 12. A re-treatment extension study was conducted in 71 CZP PASI 75 responders who relapsed during a 12- to 24-week observation period without treatment.PASI 75 was achieved by 44/59 (75%), 48/58 (83%) and 4/59 (7%) patients in the CZP 200 mg, CZP 400 mg and placebo groups, respectively (P < 0·001 for both treatment arms vs. placebo). A PGA score of clear-almost clear was achieved by 53%, 72% and 2%, respectively (P < 0·001 for both treatment arms vs. placebo). In the re-treatment study median PASI scores were similar at week 12 in the first treatment and re-treatment periods for both CZP groups. Serious adverse events occurred in 3%, 5% and 2% of CZP 200 mg, CZP 400 mg and placebo patients, respectively.Treatment with CZP significantly improved psoriasis at week 12. Similar efficacy was observed at week 12 in patients receiving re-treatment for loss of response after drug withdrawal.
Interleukin 2 (IL 2) and interferon-gamma production by T lymphocytes from patients with B-chronic lymphocytic leukemia: evidence that normally released IL 2 is absorbed by the neoplastic B cell population
Authors: R Foa, M Giovarelli, C Jemma, MT Fierro, P Lusso, ML Ferrando, F Lauria, G Forni
Journal: Blood (1985)
Shock Wave Therapy for Treatment of Plantar Fasciitis
Authors: Argil J. Wheelock
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group
Authors: MG Britton, JS Earnshaw, JB Palmer
Journal: European Respiratory Journal (1992)

The efficacy and tolerability of salmeterol, 50 micrograms b.i.d. was compared for three months with salbutamol, 200 micrograms q.i.d., administered from metered-dose inhaler. For the following nine months, safety and clinic lung function was monitored on salmeterol, 50 micrograms b.i.d., compared with salbutamol, 200 micrograms b.i.d. This comparison was made in a multicentre, double-blind, parallel-group study of 667 moderate asthmatics, who had a forced expiratory volume in one second (FEV1) or peak expiratory flow rate (PEFR) &gt; 50% predicted, a 15% reversibility to inhaled salbutamol and who were experiencing symptoms. Throughout the first three month treatment period, both morning and evening PEFR were significantly higher on treatment with salmeterol than salbutamol (mean differences between the treatments 30 l.min-1 for morning, p &lt; 0.001, and 11 l.min-1 for evening, p &lt; 0.01). In addition, the diurnal variation in PEFR, nocturnal and daytime symptoms and use of additional salbutamol were significantly lower in the salmeterol treated group. This improvement was also apparent in the separate subpopulations of patients taking no concurrent glucocorticosteroid or concurrent inhaled and/or oral glucocorticosteroids. Both treatments were well-tolerated throughout the 12 months of treatment. There was a lower incidence of asthma and related events during salmeterol treatment compared to salbutamol treatment subgroups. The results of the study clearly demonstrate that salmeterol, 50 micrograms b.i.d., is well-tolerated and more effective than salbutamol, 200 micrograms q.i.d., in the treatment of moderate asthma.
Synthetic Thyroxine vs Dessicated Thyroid
Authors: Edward M Lichten
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Right ventricular outflow tract characteristics can predict successful outcome for percutaneous pulmonary valve implantation - A "learning curve" analysis of a novel technique
Authors: Stefania Marazia, Sachin Khambadkone, Louise Coats, Giovanni Parenzan, Johannes Nordmeyer, Twin-Yaen Lee, John Deanfield, Shay Cullen, Andrew Taylor, Philipp Bonhoeffer
Journal: Circulation (2006)
Prospective study of a panfungal PCR assay followed by sequencing, for the detection of fungal DNA in normally sterile specimens in a clinical setting: a complementary tool in the diagnosis of invasive fungal disease?
Authors: B. Babouee, D. Goldenberger, L. Elzi, D. Lardinois, C. Sadowski-Cron, L. Bubendorf, S. Savic Prince, M. Battegay, R. Frei, M. Weisser
Journal: Clinical Microbiology and Infection (2013)
Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
Authors: Christina Charles‐Schoeman, Roy Fleischmann, Jean Davignon, Howard Schwartz, Scott M. Turner, Carine Beysen, Mark Milad, Marc K. Hellerstein, Zhen Luo, Irina V. Kaplan, Richard Riese, Andrea Zuckerman, Iain B. McInnes
Journal: Arthritis & Rheumatology (2014)

Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Systemic inflammation is proposed to play a fundamental role in the altered lipid metabolism associated with RA; however, the underlying mechanisms are unknown. We undertook this study to compare cholesterol and lipoprotein kinetics in patients with active RA with those in matched healthy volunteers.This was a phase I open-label mechanism-of-action study. Cholesterol and lipoprotein kinetics were assessed with (13) C-cholesterol and (13) C-leucine infusions. RA patients were reevaluated after receiving oral tofacitinib 10 mg twice daily for 6 weeks.Levels of high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total cholesterol, and apolipoprotein A-I (Apo A-I) as well as HDL cholesterol particle number were lower in RA patients (n = 36) than in healthy volunteers (n = 33). In contrast, the cholesterol ester fractional catabolic rate was higher in RA patients, but no differences were observed in cholesterol ester transfer protein, cholesterol ester production rate, HDL-associated Apo A-I fractional catabolic rate, or LDL-associated Apo B fractional catabolic rate. Following tofacitinib treatment in RA patients, the cholesterol ester fractional catabolic rate decreased and cholesterol levels increased. The decrease in cholesterol ester fractional catabolic rate correlated significantly with the increase in HDL cholesterol. Additionally, HDL cholesterol particle number increased and markers of HDL cholesterol function improved.This is the first study to assess cholesterol and lipoprotein kinetics in patients with active RA and matched healthy volunteers. The data suggest that low cholesterol levels in patients with active RA may be driven by increases in cholesterol ester catabolism. Tofacitinib treatment reduced cholesterol ester catabolism, thereby increasing cholesterol levels toward those in healthy volunteers, and markers of antiatherogenic HDL function improved.
Why dermatologists shouldn’t practise in red light districts
Authors: B.L. Diffey
Journal: British Journal of Dermatology (2011)

Journal Article Why dermatologists shouldn’t practise in red light districts Get access B.L. Diffey B.L. Diffey Dermatological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, U.K. E‐mail: brian.diffey@ncl.ac.uk Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 165, Issue 4, 1 October 2011, Page 925, https://doi.org/10.1111/j.1365-2133.2011.10484.x Published: 01 October 2011
Green tea polyphenol, (-)-epigallocatechin-3-gallate, induces oxidative stress and DNA damage in cancer cell lines, xenograft tumors, and mouse liver
Authors: Zhe Hou, Hang Xiao, Joshua Lambert, Hui You, Chung S. Yang
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

4896 

(-)-Epigallocatechin-3-gallate (EGCG), the major polyphenol in green tea, has been shown to inhibit cancer cell growth and tumorigenesis in animal models. Our previous work has shown that the auto-oxidation of EGCG in the culture medium caused apoptosis and inactivation of growth factor receptors. In the present studies with superoxide dismutase (SOD) and catalase in the medium to stabilize EGCG, EGCG (20 or 50 μM) could still induce intracellular ROS in both esophageal squamous cell carcinoma KYSE 150 and non-small cell lung cancer H1299 cells determined by dichlorofluorescin staining. These signals can be greatly reduced by the presence of N -acetyl-cysteine, which can penetrate the cell membrane and reach the cytosol. As a consequence of ROS induction, 15 μM EGCG increased the level of phospho-H2A.X, a DNA double strand break marker, in H1299 cells in the presence of SOD and catalase after 48 h of incubation. This treatment also caused 50% inhibition on H1299 cell growth and 25% cells in early apoptotic state. This suggests that EGCG-induced ROS could damage DNA and possibly contribute to the growth inhibition effect. Utilizing the tissue and tumor samples from an H1299 xenograft study, we observed that EGCG administration to NCR nu/nu mice could induce the up-regulation of oxidative stress and DNA damage markers. In the mouse liver, i.p. injection of 40 or 80 mg/kg EGCG daily for 4 weeks led to the increase of phospho-H2A.X and metallothionein expression, suggesting the presence of oxidative stress. EGCG administration through diet (0.2%) or in drinking fluid (0.32%) did not have such effects. The growth of H1299 xenograft tumors was inhibited by 50% as a result of i.p. injection of 40 mg/kg EGCG daily for 4 weeks. Phospho-H2A.X level was significantly increased in tumors of the treatment group compared to those of control. EGCG is generally considered to be an antioxidant. More studies are needed to determine whether the pro-oxidative activities of EGCG can contribute to tumor growth inhibition and oxidative stress to the host animals (supported by NIH grants CA 88961 and CA 56673).
291. Enhanced Therapeutic Effect of Adenoviral Vector-Mediated RTVP-1 Gene Therapy in Combination with Irradiation for Prostate Cancer
Authors: Tetsuo Fujita, Koji Naruishi, Nobuyuki Kusaka, Takefumi Satoh, Xiaorong Ji, Jianxiang Wang, Xiaohong Zhu, Guang Yang, Alexei A. Goltsov, Terry L. Timme, Maria T. Vlachaki, Bin S. Teh, E. Brian Butler, Timothy C. Thompson
Journal: Molecular Therapy (2004)

Introduction: We previously documented that adenoviral vector-mediated murine RTVP-1 (AdmRTVP-1) gene therapy significantly suppresses the growth of mouse prostate cancer through direct cytotoxicity and the induction of a systemic anti-tumor immune response. This study explores the potential benefits of combining AdmRTVP-1 or adenoviral vector-mediated human RTVP-1 (AdhRTVP-1) gene therapy with irradiation (XRT) to enhance therapeutic efficacy in a subcutaneous prostate cancer model.
Controversy in primary care: Does continuity in general practice really matter? Commentary: A patient's perspective of continuity
Authors: B. Guthrie
Journal: BMJ (2000)

# Does continuity in general practice really matter? {#article-title-2}

Continuity is an official core value of general practice in the United Kingdom,1 but there are at least two potentially conflicting definitions of it. Both definitions are powerfully expressed in a recent report from the BMA, entitled Shaping Tomorrow .2

For general practitioners, continuity of care has traditionally meant that a patient visits the same doctor. 3 4 What matters is personal continuity, in which an ongoing doctor-patient relationship ensures that care takes account of the patient's personal and social context. By contrast, recent statements from the NHS Executive emphasise the importance of consistency and coordination of care.5 From this perspective, continuity can be enhanced by appropriate organisation, guidelines, and electronic medical records, irrespective of which doctor is seen.

#### Summary points

Continuity, in the sense of visiting the same doctor, is a core value of general practice in the United Kingdom

It is increasingly presented as “old fashioned” and in opposition to the development and modernisation of primary care

The implicit choice between personal continuity and modern care is false; what evidence there is suggests that patients prefer services providing personal continuity, and this may also reduce the use of investigations and admissions to hospital

If general practitioners really believe that it matters that a patient visits the same doctor, they need to ensure that this is taken into account in the development of primary care

Most research about the impact of continuity of care has been conducted in antenatal care or in specialist care settings in the United States.6-10 Generalising these results to general practice in the United Kingdom is possible but problematic. Research shows that a patient's enablement and satisfaction with a consultation is strongly associated with visiting the same doctor.11-13 Patient satisfaction is also higher in practices that are small, non-training, or have personal …
Tropical Diseases, A Manual of the Diseases of Warm Climates.
Authors: Patrick Manson
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal